Condition
X-linked Lymphoproliferative Disease
Total Trials
5
Recruiting
0
Active
2
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
Termination Rate
20.0%
1 terminated out of 5 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
100%
2 of 2 completed with results
Key Signals
2 with results67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 1 (2)
P 2 (1)
Trial Status
Completed2
Active Not Recruiting2
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT01652092Not ApplicableActive Not Recruiting
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
NCT01494103Phase 1Active Not Recruiting
Administration of Donor T Cells With the Caspase-9 Suicide Gene
NCT03513328Phase 1Completed
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
NCT00359411CompletedPrimary
Genetic Studies of X-linked Lymphoproliferative Disease
NCT02512679Phase 2Terminated
Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells
Showing all 5 trials